Healthcare / Medical DevicesOslo
$0.97
-0.04 (-3.76%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-29.3M · quality 61.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
3/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$132M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-162.4%
↓Gross Margin
25.0%
↓Debt/Equity
1.03
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-1.2%
FCF CAGR
—
FCF margin
-138.1%
FCF / Net income
0.53x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $18.8M · net income $-48.6M · FCF $-26.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $18.8M | $18.8M | $17.2M | $27.9M | $19.5M |
| Net Income | $-48.6M | $-48.6M | $-58.7M | $-135.1M | $-50.8M |
| EBITDA | $-30.1M | $-30.1M | $-34.8M | $-114.3M | $-36.0M |
| EPS | -0.73 | -0.73 | -3.95 | -20.55 | -8.99 |
| Gross Margin | 25.0% | 25.0% | 10.6% | 33.2% | 26.5% |
| Operating Margin | -198.5% | -198.5% | -257.7% | -204.4% | -303.0% |
| Net Margin | -258.6% | -258.6% | -340.9% | -483.5% | -260.2% |
| Balance Sheet | |||||
| Debt/Equity | 1.03 | 1.03 | 3.94 | 1.37 | 0.35 |
| Current Ratio | 0.48 | 0.48 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-26.0M | $-26.0M | $-29.3M | $-32.5M | $-56.3M |
| Returns | |||||
| ROE | -162.4% | -162.4% | -277.9% | -330.6% | -36.7% |
| Valuation | |||||
| P/B | 2.16 | 2.16 | 3.97 | 0.78 | 1.20 |
| Growth & Yield | |||||
| Revenue Growth | 9.2% | 9.2% | -38.3% | 43.1% | — |
| EPS Growth | 81.5% | 81.5% | 80.8% | -128.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-15.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.95 → -0.73
Residual
-15.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.